Dianthus Therapeutics (DNTH) Price & Analysis

Compare

349 Followers

DNTH Stock Chart & Stats

Day’s Range― - ―

52-Week Range$13.37 - $32.27

Previous CloseN/A

Volume29.07K

Average Volume (3M)360.31K

Market Cap

$640.55M

Enterprise Value$411.31M

Total Cash (Recent Filing)$257.39M

Total Debt (Recent Filing)$1.33M

Price to Earnings (P/E)―

Beta1.12

Next Earnings

Nov 06, 2025

EPS Estimate

-0.9

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.88

Shares Outstanding32,188,347

10 Day Avg. Volume341,845

30 Day Avg. Volume360,312

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.64

Enterprise Value/Revenue84.74

Enterprise Value/Gross Profit86.50

Enterprise Value/Ebitda-3.17

Forecast

1Y Price Target

$50.29

Price Target Upside141.20% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe Phase II MaGic trial of claseprubart in generalized myasthenia gravis is expected to provide significant data.

Drug EfficacyClaseprubart is expected to demonstrate a favorable safety profile and equal to better efficacy on key secondary endpoints.

Financial StabilityDianthus had approximately $309.1M in cash, cash equivalents, and investments, which is believed to be sufficient to fund planned operations into 2H27, providing a solid financial foundation.

Bears Say

Market CompetitionWith recent FcRn antagonist approvals, gMG is an increasingly competitive space.

Revenue PerformanceThe company reported license revenue for 2Q25 significantly below consensus estimates, which could raise concerns about short-term financial performance.

Dianthus Therapeutics News

Dianthus reports Q2 EPS (88c), consensus (87c)

Reports Q2 revenue $193,000, consensus $864,670. “We look forward to reporting top-line Phase 2 results from our MaGic...

8d ago

DNTH

3 Best Stocks to Buy Now, 7/29/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

17d ago

DNTH

HRMY

Dianthus price target raised to $92 from $84 at Guggenheim

Guggenheim raised the firm’s price target on Dianthus (DNTH) to $92 from $84 and keeps a Buy rating...

18d ago

DNTH

Dianthus Therapeutics: Promising Developments and Market Potential Drive Buy Rating

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Dianthus Therapeutics, retaining the price target of...

2d ago

DNTH

Promising Clinical Developments and Financial Stability Drive Buy Recommendation for Dianthus Therapeutics

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Dianthus Therapeutics and keeping the price target...

4d ago

DNTH

Dianthus Therapeutics Reports Q2 2025 Financial Results

Dianthus Therapeutics, Inc. ( ($DNTH) ) has released its Q2 earnings. Here is a breakdown of the information...

7d ago

DNTH

Dianthus Therapeutics: Promising Prospects with DNTH103 and Strong Financial Position Support Buy Rating

TD Cowen analyst Yaron Werber has maintained their bullish stance on DNTH stock, giving a Buy rating today....

8d ago

DNTH

Promising Outlook for Dianthus Therapeutics: Buy Rating on Claseprubart’s Potential in gMG

William Blair analyst Myles Minter has maintained their bullish stance on DNTH stock, giving a Buy rating today....

8d ago

DNTH

Dianthus Therapeutics’ CAPTIVATE Study: A Potential Game-Changer for CIDP Treatment

Dianthus Therapeutics, Inc. (($DNTH)) announced an update on their ongoing clinical study. The CAPTIVATE study, officially titled ‘A...

18d ago

DNTH

Dianthus Therapeutics’ DNTH103: A Promising Complement Inhibitor with Upcoming Catalysts

William Blair analyst Myles Minter has maintained their bullish stance on DNTH stock, giving a Buy rating today....

1M ago

DNTH

Dianthus initiated with an Outperform at William Blair

William Blair initiated coverage of Dianthus (DNTH) with an Outperform rating. Dianthus is a clinical-stage biotech company developing...

1M ago

DNTH

Dianthus Therapeutics: Promising Prospects in Autoimmune Complement Inhibitor Market with DNTH103 Advancements

Myles Minter, an analyst from William Blair, has initiated a new Buy rating on Dianthus Therapeutics (DNTH). Myles...

1M ago

DNTH

Optimistic Buy Rating for Dianthus Therapeutics Amidst Promising C1s Inhibition Developments

Dianthus Therapeutics (DNTH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

2M ago

DNTH

Dianthus price target lowered to $50 from $58 at Baird

Baird lowered the firm’s price target on Dianthus (DNTH) to $50 from $58 and keeps an Outperform rating...

3M ago

DNTH

DNTH FAQ

What was Dianthus Therapeutics’s price range in the past 12 months?

Dianthus Therapeutics lowest stock price was $13.37 and its highest was $32.27 in the past 12 months.

What is Dianthus Therapeutics’s market cap?

Dianthus Therapeutics’s market cap is $640.55M.

When is Dianthus Therapeutics’s upcoming earnings report date?

Dianthus Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 83 days.

How were Dianthus Therapeutics’s earnings last quarter?

Dianthus Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.872 by -$0.008.

Is Dianthus Therapeutics overvalued?

According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dianthus Therapeutics pay dividends?

Dianthus Therapeutics does not currently pay dividends.

What is Dianthus Therapeutics’s EPS estimate?

Dianthus Therapeutics’s EPS estimate is -0.9.

How many shares outstanding does Dianthus Therapeutics have?

Dianthus Therapeutics has 32,188,347 shares outstanding.

What happened to Dianthus Therapeutics’s price movement after its last earnings report?

Dianthus Therapeutics reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.872. Following the earnings report the stock price went down -2.037%.

Which hedge fund is a major shareholder of Dianthus Therapeutics?

Currently, no hedge funds are holding shares in DNTH

Dianthus Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-34.71%

Trailing 12-Months

Asset Growth

-11.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dianthus Therapeutics

Dianthus Therapeutics (DNTH) is a biotechnology company focused on developing innovative therapies for serious autoimmune diseases. The company specializes in the discovery and commercialization of monoclonal antibodies and other biologics that target specific immune pathways. Dianthus is committed to addressing unmet medical needs and enhancing patient care through its advanced therapeutic solutions in the biopharmaceutical sector.

Dianthus Therapeutics (DNTH) Earnings & Revenues

Historic Earnings Reports

DNTH Stock 12 Month Forecast

Average Price Target

$50.29

▲(141.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","54":"$54","93":"$93","34.5":"$34.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$92.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,34.5,54,73.5,93],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.59,26.083076923076923,31.576153846153844,37.06923076923077,42.56230769230769,48.05538461538461,53.54846153846154,59.041538461538465,64.53461538461538,70.0276923076923,75.52076923076923,81.01384615384615,86.50692307692307,{"y":92,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.59,22.874615384615385,25.159230769230767,27.443846153846152,29.728461538461538,32.01307692307692,34.29769230769231,36.582307692307694,38.86692307692307,41.151538461538465,43.43615384615384,45.72076923076923,48.005384615384614,{"y":50.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.59,20.62153846153846,20.653076923076924,20.684615384615384,20.716153846153848,20.747692307692308,20.779230769230768,20.810769230769232,20.842307692307692,20.873846153846152,20.905384615384616,20.936923076923076,20.96846153846154,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.83,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.88,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >